Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05457582
Other study ID # NMU20220701
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 30, 2023
Est. completion date January 30, 2029

Study information

Verified date April 2024
Source Nanjing First Hospital, Nanjing Medical University
Contact Shao-Liang Chen, MD, PhD
Phone +86-25-52271351
Email chmengx@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective was to evaluate the effect of PCSK 9 Inhibitor (initiated within 4 h from PCI for the culprit lesion) with high-intensity statin treatment, compared to placebo with high-intensity statin treatment, on cardiovascular events (including cardiovascular death, myocardial infarction, stroke, re-hospitalization due to acute coronary syndromes or heart failure, or any ischemia-driven coronary revascularization) in patients with acute coronary syndrome and multiple lesions.


Description:

Patients with acute coronary syndrome (ACS) are at high-risk. ACS patients are commonly associated with multiple lesions or multivessel disease. Percutaneous coronary intervention (PCI) is an effective treatment for culprit lesions in ACS. Statin at high-intensity is recommended by current guidelines in order to prevent/slow the progression of non-culprit disease or restenosis. PCSK9 inhibitor serves as the most powerful medication in lowering LDL via promoting the expression of LDL receptors in the liver. However, if the combination of PCSK9 inhibitor with high-intensity statin treatment could significantly reduce the cardiovascular events in patients with ACS who underwent PCI remains unknown.


Recruitment information / eligibility

Status Recruiting
Enrollment 1212
Est. completion date January 30, 2029
Est. primary completion date January 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The subject, or their legal guardian, must have a clear understanding of the trial's design and treatment procedures. They must provide written informed consent before any trial-specific tests or procedures are conducted. 2. Both male and female subjects aged =18 years. 3. Subjects who have experienced an ACS and have undergone PCI for culprit lesions (either QFR or FFR < 0.8) are eligible. ACS is defined as: (1) Unstable angina (characterized by rest pain lasting between 5 and 30 minutes or worsening exertional angina accompanied by either transient ST segment depression or elevation, or angiography revealing visually estimated diameter stenosis of 90% or greater, or a ruptured plaque or thrombotic lesion), or (2) Non-ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and non-ST segment elevation, or (3) ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and ST-segment elevation. 4. Low-density lipoprotein cholesterol levels must meet the following criteria: 1. Low-density lipoprotein cholesterol =70 mg/dL (=1.8 mmol/L) in patients who have been on a stable high-intensity statin regimen for at least 4 weeks before enrollment. 2. Low-density lipoprotein cholesterol =90 mg/dL (=2.3 mmol/L) in patients who have been on a moderate or low-intensity statin regimen before enrollment. 3. Low-density lipoprotein cholesterol =125 mg/dL (=3.2 mmol/L) in patients who are statin-naïve or have not been on a stable statin regimen for at least 4 weeks before enrollment. 5. Subjects must have at least one culprit lesion for ACS in a major native coronary artery (diameter stenosis >70% with a QFR or FFR<0.8), and have at least one non-culprit vessel disease (diameter stenosis =70% with a QFR or FFR =0.8). Exclusion Criteria: 1. Fasting serum triglyceride levels exceeding 400 mg/dL (exceeding 4.52 mmol/L) before randomization. 2. Coronary artery disease is located within a saphenous vein graft or an arterial graft. 3. Residual diameter stenosis greater than 50% as determined by visual examination after percutaneous coronary intervention of the culprit lesion. 4. TIMI (Thrombolysis in Myocardial Infarction) flow less than 3 in the culprit vessel after PCI. 5. Unstable clinical status, characterized by hemodynamic (including cardiogenic shock) or electrical instability. 6. Uncontrolled hypertension, indicated by multiple readings with systolic blood pressure (SBP) exceeding 180 mmHg or diastolic blood pressure (DBP) exceeding 110 mmHg. 7. New York Heart Association (NYHA) Class III or IV, and an already known left ventricular ejection fraction (LVEF) below 30%. 8. Known history of hemorrhagic stroke in last 180 days before randomization. 9. Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response that has not been controlled by medications in the past 3 months before screening. 10. Severe renal dysfunction, defined by an estimated glomerular filtration rate (eGFR) below 30 ml/min/1.73m². 11. Active liver disease or hepatic dysfunction. 12. Known intolerance to rosuvastatin or any statin. 13. Known allergy to contrast medium, heparin, aspirin, ticagrelor, prasugrel, or clopidogrel. 14. Subjects who have previously received PCSK9 inhibitors. 15. Subjects who have received cholesterol ester transfer protein inhibitors within the past 12 months before enrollment. 16. Treatment with systemic steroids or systemic cyclosporine within the past 3 months. 17. Known active infection or major hematologic, metabolic, or endocrine dysfunction, as determined by the Investigator. 18. Planned non-cardiac surgery within the next 12 months. 19. Subjects who will not be able to attend the required study visits, as determined by the Investigator. 20. Currently enrolled in another investigational device or drug study. 21. History of cancer within the past 5 years, unless adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer. 22. Estimated life expectancy of less than 12 months. 23. Female of childbearing potential (age <50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy, or hysterectomy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo plus high-intensity statin
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
PCSK 9 Inhibitor plus high-intensity statin
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).

Locations

Country Name City State
China Nanjing First Hospital Nanjing Jiangsu

Sponsors (3)

Lead Sponsor Collaborator
Nanjing First Hospital, Nanjing Medical University Nanjing Medical University, National Natural Science Foundation of China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiovascular events Cardiovascular events defined as the composite of cardiovascular death, myocardial infarction, stroke or transit ischemic attack, re-hospitalization due to unstable angina or heart failure, or any ischemia-driven coronary revascularization. 12 months after randomization
Secondary Cardiovascular death It will be adjudicated by an independent external CEC according to protocol defined definition. 12 months after randomization
Secondary All cause death It is defined as any death from randomization to the last visit. 12 months after randomization
Secondary Myocardial infarction It will be adjudicated by an independent external CEC. 12 months after randomization
Secondary Stroke stroke will be adjudicated by an independent external CEC. 12 months after randomization
Secondary Ischemia-driven coronary revascularization It will be adjudicated by an independent external CEC. 12 months after randomization
Secondary Re-hospitalization due to unstable angina or heart failure It will be adjudicated by an independent external CEC. 12 months after randomization
Secondary Diagnostic malignant tumor It will be adjudicated by an independent external CEC. 12 months after randomization
Secondary PCSK9 inhibitors or statin intolerance It will be adjudicated by an independent external CEC. 12 months after randomization
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study